Search
Daiichi Sankyo and AstraZeneca's New Antibody-Drug Conjugate for Cancer Receives Approval in China
2 week ago /
Read about 0 minute
Author：小编
China's National Medical Products Administration has granted approval for Datroyu® (generic name: Datopotamab Deruxtecan Injection) for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have previously undergone endocrine therapy and chemotherapy. Developed in collaboration by Daiichi Sankyo and AstraZeneca, this drug is a TROP2-targeted antibody-drug conjugate (ADC) utilizing Daiichi Sankyo's exclusive DXd ADC technology. As the second breast cancer treatment drug based on DXd ADC technology approved by Daiichi Sankyo in China, following Enhertu, Datroyu® further diversifies the treatment options available for breast cancer patients.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
